TBX19
Basic information
Region (hg38): 1:168280877-168314426
Links
Phenotypes
GenCC
Source:
- congenital isolated adrenocorticotropic hormone deficiency (Definitive), mode of inheritance: AR
- congenital isolated adrenocorticotropic hormone deficiency (Strong), mode of inheritance: AR
- congenital isolated adrenocorticotropic hormone deficiency (Supportive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Adrenocorticotropic hormone deficiency | AR | Endocrine | Individuals may have severe neonatal hypoglycemia, and treatment of adrenocortical insufficiency (eg, with hydrocortisone, fludricortisone) can be effective | Endocrine | 4295129; 6314808; 2830787; 8222301; 11290323; 15613420 |
ClinVar
This is a list of variants' phenotypes submitted to
- Congenital isolated adrenocorticotropic hormone deficiency (6 variants)
- not provided (3 variants)
- TBX19-related disorder (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TBX19 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 12 | 18 | ||||
missense | 43 | 48 | ||||
nonsense | 3 | |||||
start loss | 0 | |||||
frameshift | 3 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 3 | 1 | 4 | |||
non coding | 23 | 11 | 16 | 50 | ||
Total | 7 | 5 | 67 | 24 | 22 |
Highest pathogenic variant AF is 0.000105
Variants in TBX19
This is a list of pathogenic ClinVar variants found in the TBX19 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-168281070-G-A | Congenital isolated adrenocorticotropic hormone deficiency | Benign (Apr 27, 2017) | ||
1-168281088-C-T | TBX19-related disorder | Likely benign (Aug 09, 2019) | ||
1-168281111-C-A | Likely benign (Jan 30, 2023) | |||
1-168281129-T-G | Congenital isolated adrenocorticotropic hormone deficiency | Uncertain significance (Jan 13, 2018) | ||
1-168281152-A-G | Inborn genetic diseases | Uncertain significance (Mar 06, 2023) | ||
1-168281161-AGAGT-A | Inborn genetic diseases | Pathogenic (Jul 25, 2014) | ||
1-168281168-G-A | Benign (Dec 25, 2022) | |||
1-168281185-A-C | Inborn genetic diseases | Uncertain significance (May 24, 2023) | ||
1-168281190-G-C | Inborn genetic diseases | Uncertain significance (Dec 16, 2021) | ||
1-168281195-C-T | Congenital isolated adrenocorticotropic hormone deficiency • TBX19-related disorder | Benign (Jan 13, 2024) | ||
1-168281244-CAG-C | Congenital isolated adrenocorticotropic hormone deficiency | Pathogenic (Jun 19, 2018) | ||
1-168281284-A-G | Congenital isolated adrenocorticotropic hormone deficiency | Uncertain significance (Jan 12, 2018) | ||
1-168281313-C-T | Likely benign (Feb 14, 2023) | |||
1-168291157-T-C | Congenital isolated adrenocorticotropic hormone deficiency • not specified • TBX19-related disorder | Conflicting classifications of pathogenicity (Jul 01, 2024) | ||
1-168291162-G-A | Congenital isolated adrenocorticotropic hormone deficiency | Likely pathogenic (Sep 23, 2021) | ||
1-168291166-G-T | Adrenal insufficiency | Uncertain significance (Nov 25, 2011) | ||
1-168291182-A-T | Inborn genetic diseases | Uncertain significance (Aug 12, 2022) | ||
1-168291213-T-G | Congenital isolated adrenocorticotropic hormone deficiency | Pathogenic (Oct 01, 2007) | ||
1-168291217-C-T | Likely benign (Nov 19, 2023) | |||
1-168291218-TC-T | Congenital isolated adrenocorticotropic hormone deficiency | Pathogenic (Oct 22, 2012) | ||
1-168291246-A-G | Uncertain significance (May 04, 2022) | |||
1-168291254-C-T | Uncertain significance (Sep 23, 2021) | |||
1-168291265-C-T | Likely benign (Sep 07, 2022) | |||
1-168291266-G-A | Congenital isolated adrenocorticotropic hormone deficiency | Uncertain significance (Oct 22, 2023) | ||
1-168291271-C-T | Congenital isolated adrenocorticotropic hormone deficiency | Conflicting classifications of pathogenicity (Oct 15, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TBX19 | protein_coding | protein_coding | ENST00000367821 | 8 | 33387 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000711 | 0.912 | 125635 | 0 | 113 | 125748 | 0.000449 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.564 | 228 | 253 | 0.900 | 0.0000150 | 2919 |
Missense in Polyphen | 66 | 87.816 | 0.75157 | 1073 | ||
Synonymous | -0.567 | 112 | 105 | 1.07 | 0.00000731 | 924 |
Loss of Function | 1.63 | 11 | 18.6 | 0.591 | 9.63e-7 | 213 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000716 | 0.000716 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00185 | 0.00185 |
European (Non-Finnish) | 0.000432 | 0.000431 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.00 | 0.00 |
Other | 0.000652 | 0.000652 |
dbNSFP
Source:
- Function
- FUNCTION: Transcriptional regulator involved in developmental processes. Can activate POMC gene expression and repress the alpha glycoprotein subunit and thyroid-stimulating hormone beta promoters. {ECO:0000269|PubMed:11290323}.;
- Disease
- DISEASE: ACTH deficiency, isolated (IAD) [MIM:201400]: An autosomal recessive disorder that is characterized by adrenal insufficiency symptoms, such as weight loss, lack of appetite (anorexia), weakness, nausea, vomiting and low blood pressure (hypotension). The pituitary hormone ACTH is decreased or absent, and other cortisol and other steroid hormone levels in the blood are abnormally low. {ECO:0000269|PubMed:11290323}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Corticotropin-releasing hormone signaling pathway
(Consensus)
Recessive Scores
- pRec
- 0.221
Intolerance Scores
- loftool
- 0.278
- rvis_EVS
- -0.96
- rvis_percentile_EVS
- 9.17
Haploinsufficiency Scores
- pHI
- 0.394
- hipred
- N
- hipred_score
- 0.350
- ghis
- 0.550
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.614
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tbx19
- Phenotype
- homeostasis/metabolism phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); endocrine/exocrine gland phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); pigmentation phenotype;
Gene ontology
- Biological process
- regulation of transcription by RNA polymerase II;anatomical structure morphogenesis;pituitary gland development;regulation of cell population proliferation;cell fate commitment;regulation of cell differentiation;positive regulation of transcription by RNA polymerase II
- Cellular component
- nucleus
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;enhancer sequence-specific DNA binding;DNA-binding transcription activator activity, RNA polymerase II-specific